Kaplan-Meier Survival Analysis: Practical Insights for Clinicians





Kaplan-Meier Estimate, Survival Analysis


This article aims to provide a guide that will help healthcare professionals and clinical researchers from all fields that deal with Kaplan-Meier curves. Survival analysis methods are among the most frequently used in the medical sciences and in clinical research. Overall survival, progression free survival, time to recurrence, or any other clinically relevant parameter represented by a Kaplan-Meier curve will be discussed. We will present a practical and straightforward interpretation of these curves, setting aside intricate mathematical considerations. Our focus will be on essential concepts that interface with biological sciences and medicine in order to guarantee proficiency in one of the most popular yet frequently misunderstood methods in clinical research. Being familiar with these concepts is not only essential for designing new clinical studies but also for critically assessing and interpreting published data.


Download data is not yet available.


De La Mata J, Blanco FJ, Gomez-Reino JJ. Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients. Ann Rheum Dis. 1995;54:881-5.

Zhang J, Ren P, Wang Y, Feng S, Wang C, Shen X, et al. Serum matrix metalloproteinase-7 level is associated with fibrosis and renal survival in patients with IgA nephropathy. Kidney Blood Press Res. 2017;42:541-52.

Conden E, Rosenblad A, Wagner P, Leppert J, Ekselius L, Aslund C. Is type D personality an independent risk factor for recurrent myocardial infarction or all-cause mortality in post-acute myocardial infarction patients? Eur J Prev Cardiol. 2017;24:522-33.

Turkson AJ, Ayiah-Mensah F, Nimoh V. Handling censoring and censored data in survival analysis: a standalone systematic literature review. Int J Math Math Sci. 2021;2021:1-16.

Lee EC, Kim SH, Park H, Lee SD, Lee SA, Park SJ. Survival analysis after liver resection for hepatocellular carcinoma: a consecutive cohort of 1002 patients. J Gastro Hepatol. 2017;32:1055-63.

Zwiener I, Blettner M, Hommel G. Survival analysis: part 15 of a series on evaluation of scientific publications. Dtsch Arztebl Int. 2011;108:163-9.

Ryu T, Takami Y, Wada Y, Tateishi M, Matsushima H, Yoshitomi M, et al. Oncological outcomes after hepatic resection and/or surgical microwave ablation for liver metastasis from gastric cancer. Asian J Surg. 2019;42:100-5.

National Cancer Institute. NCI Dictionary of Cancer Terms. [cited 2022 Jun 28]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/progression-free-survival.

Yan WT, Quan B, Xing H, Wu MC, Yang T. Time to recurrence, but not recurrence-free survival, should be the endpoint used to predict early recurrence after HCC resection. J Hepatol. 2019;70:570-1.




How to Cite

Gomes AP, Costa B, Marques R, Nunes V, Coelho C. Kaplan-Meier Survival Analysis: Practical Insights for Clinicians. Acta Med Port [Internet]. 2024 Apr. 1 [cited 2024 Apr. 23];37(4):280-5. Available from: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/21080



Review Articles